Overview

• Emma Walmsley will leave GSK’s board at the end of 2025 and remain employed through September 30, 2026.
• GSK shares rose about 3.5% in early trading after the succession was announced.
• Luke Miels, 50, is GSK’s chief commercial officer overseeing global medicines and vaccines since 2017, with prior senior roles at AstraZeneca, Sanofi and Roche.
• The leadership change lands as the U.S. considers 100% tariffs on branded drugs, with GSK having outlined $30 billion of planned U.S. investment over five years.
• Miels’s base salary will be about £1.38 million with bonus and long-term incentives, and he is charged with delivering sales of more than £40 billion by 2031.